Fresenius Investor Relations

💡 Innovation in hospitals is key! Fresenius Helios is Europe’s leading private network of hospitals and outpatient clinics and is continuously expanding its role. Curious about their success stories in 2024? Check out the article below to discover how they’re driving medical excellence and advancing digital solutions. 💻 Read more in the Fresenius Online Annual Report 2024: https://lnkd.in/eqbZyeKW #AnnualReport2024 #FutureFresenius #CommittedToLife

📢 News from our #Biosimilars pipeline! Fresenius announced yesterday that the Biologics License Application (BLA) for the denosumab biosimilars of our Operating Company Fresenius Kabi has been approved by the U.S. Food and Drug Administration (FDA). In addition, Fresenius Kabi has reached a global settlement with Amgen, allowing the launch of these biosimilars in the US from mid-2025 and in Europe later in H2 of 2025, subject to regulatory approval. Congratulations to our colleagues at Fresenius Kabi – this is fantastic news and marks further progress on our journey towards #FutureFresenius! Read the full press release: https://lnkd.in/etKmSpDV Brief News: https://lnkd.in/eKqQxUBr #Biosimilars #CommittedToLife 

#FutureFresenius makes our company more innovative, more focused, more efficient! Fresenius Group has just published its Annual Report 2024: https://lnkd.in/eqbZyeKW Over the past year, Fresenius has become a stronger healthcare company delivering significant value for all our stakeholders. Learn more about our progress on our #FutureFresenius transformation and key milestones in 2024! What to discover 🔎 💻 Watch CEO Michael Sen's video message and read his letter to shareholders 💡 Explore the success stories of our core businesses Fresenius Kabi and Fresenius Helios ✅ Dive into our company’s first sustainability statement fully compliant with ESRS 📊 Check out our company’s financial performance and key figures ➡️ And much more: Management Report, Report of the Supervisory Board A huge Thank You to all teams across the company who contributed to the preparation and implementation of the Fresenius Annual Report 2024. Your teamwork and dedication highlights the power of collaboration in our organization! #TeamFresenius #AnnualReport2024 #CommittedToLife

Just wrapped up two productive days of investor meetings in Montreal and New York! 🌎 It was great to engage with new investors and introduce them to Fresenius, while also updating our existing shareholders on our latest progress. We received excellent feedback on our #FutureFresenius transformation, consistent execution, and strong FY24 results.   Our highlight included the in-depth discussions around our growing Biopharma franchise, where we are continuously expanding our molecule portfolio. We are thrilled see continued positive momentum and growing interest in Fresenius!   A big thank you to ODDO BHF for the seamless organization and highly effective meetings. Excited to continue these conversations! #Roadshow #CommittedToLife

📢 Fresenius Group Annual Report 2024 is coming soon: Next Wednesday (26 March) we will publish our online report 📊 With strategic updates, performance highlights and success stories from our core businesses, the Fresenius Annual Report 2024 provides a comprehensive summary of our progress on #FutureFresenius and our milestones in 2024! With the Annual Report 2024, we also publish our first Sustainability Statement in full compliance with the requirements of the European Corporate Sustainability Reporting Directive and the European Sustainability Reporting Standards. A big Thank You for the dedication and commitment of all teams involved in the preparation of this report, we are proud to provide our stakeholders with detailed information on our businesses, financial figures, sustainability initiatives and our goals as we move forward on our journey towards #FutureFresenius and a more sustainable future! 👉 A PDF version will also be available. Stay tuned! #AnnualReport2024 #CommittedToLife

It was a pleasure to connect with so many US investors and see their strong and growing interest in Fresenius Group at the Barclays 27th Annual Global Healthcare Conference in Miami. We provided updates on our strong FY 2024 results and our continued progress on #FutureFresenius 📈🚀. As we move into the next phase of our transformation - “Rejuvenate” - our focus remains on organic growth and structural productivity, building on our solid financial performance. A big thank you to Hassan Al-Wakeel, CFA and Jonathon Unwin for hosting us, and to all investors for the engaging discussions! We look forward to continuing the conversation. #BarcHealthcare #CommittedToLife

🚀 Strategic milestone achieved: Fresenius Group successfully reduces its stake in Fresenius Medical Care! As part of our #FutureFresenius transformation, we’ve taken another decisive step towards becoming a more focused and stronger healthcare company. 🔎 What was the transaction structure? We sold around 10.6 million shares of Fresenius Medical Care (FME) (~3.6% of its issued share capital) through an accelerated bookbuilding process. Additionally, we issued bonds exchangeable into ordinary shares with approximately 10.4 million shares underlying (~3.5%) amounting to €600 million at an interest rate of 0%. Fresenius remains the largest shareholder, retaining no less than 25% + one share in FME. 📢 Why did Fresenius reduce its stake? With the direct sale of shares, we are taking advantage of the momentum in FME’s share price performance. By issuing bonds amounting to EUR 600 million at an interest rate of 0% which are exchangeable into FME shares in the future, we can finance ourselves favorably, while at the same time continue to participate in the successful development of FME. The proceeds will be used in line with our #FutureFresenius transformation focusing on: ✔ Enhancing strategic flexibility ✔ Strengthening our balance sheet ✔ Reducing leverage ✔ Driving long-term growth & shareholder value 💡 How did the market react? The response from analysts and investors has been overwhelmingly positive! The transaction is seen as a catalyst for Fresenius, reinforcing our commitment to simplification and financial flexibility. Last week, our team attended two investor conferences in London, where the transaction was one of the key topics – widely viewed as a strong and strategic step forward. Congratulations to all teams involved! This step reflects our promise we made to all our stakeholders in the long-term: We are #CommittedtoLife! 📩 Find out more: https://lnkd.in/e9M28CWq #TeamFresenius 

After last week's strong FY/24 results, we're excited to share what we have planned for March! Here is a first preview of events including roadshows and conferences. Check out our events calendar and stay tuned for more 👉 https://lnkd.in/dGY4pER   As we are now moving into the next phase of our transformation 'REJUVENATE', maintaining an ongoing dialogue with our financial stakeholders remains a top priority! #FreseniusResults #CommittedToLife

Hear the market's reaction to Fresenius' FY24 results! 🎙️ Nick Stone, Head of Investor Relations at Fresenius, shares insights from yesterday’s London roadshow and how institutional investors and analysts view our progress on #FutureFresenius. #FreseniusResults #CommittedToLife